In other cancer types, such as melanoma and ovarian cancer, TPL2 becomes oncogenic by overexpression, or acquires gain-of-function truncations, fusions, and point mutations, leading to hyperactive MAPK, NF-κB, JNK, and p38 cascades. This evidence concerns the gene NFKB1 and cancer.